Management of chronic myeloid leukemia in France: A multicentered cross-sectional study on 538 patients

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 8, 2005, Pages 545-553

  Tardieu, Sophie ^a,f   Brun Strang, Catherine ^b   Berthaud, Patrice ^b   Michallet, Mauricette ^c   Guilhot, François ^d   Rousselot, Patrice ^e   Sambuc, Roland ^a  

^a University Hospital of Marseille   (France)

^b Rueil Malmaison Novartis Pharma SA   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Chronic myeloid leukemia; Drug use; Health care organization; Management; Multicenter study

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ADULT; AGE; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CLINICAL PRACTICE; CONSULTATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG HYPERSENSITIVITY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FRANCE; HEALTH CARE FACILITY; HEALTH CARE UTILIZATION; HEMATOLOGY; HOSPITAL DEPARTMENT; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT INFORMATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX RATIO; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE MARROW TRANSPLANTATION; COMMUNITY NETWORKS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FRANCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERFERON TYPE I, RECOMBINANT; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 23844512806     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1046     Document Type: Article

References (41)

1. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Deninger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
4. Sawyers C. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
5. Faderl S, Talpaz M, Eestrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207-219.
6. Brincker H. Population-based age and sex-specific incidence rate in the 4 main types of leukemia. Scand J Haematol 1982; 29: 241-249.
7. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukaemia: update on biology and treatment. Oncology (Huntington) 1999; 13: 169-180.
8. Ferlay J, Black RJ, Whelan SL, Parkin DM. Electronic database of cancer incidence in five continents, Vol. VII International Agency for Research on Cancer, World Health Organization and International Association of Cancer Registries. CI5VII: IARC CancerBase No. 2.
9. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edward BK (eds). SEER Cancer Statistics Review 1973-1991: Tables and Graphs. NIH Pub. National Cancer Institute: Bethesda, MD, 1994; 234.
10. Ferlay J, Bray F, Sankila R, Parkin DM. EUCAN: Cancer Incidence, Mortality and Prevalence in European Union. IARC Press: Lyon, 1999.
11. Gutierrez L, Maguire A. Prevalence of chronic myelogenous leukemia in European Union. Epidemiological report. 2000 July p. 20. Novartis on file data.
12. Institut National de la Santé et de la Recherche Médicale (INSERM). Service d'Information sur les Causes Médicales de Décès. Electronic database SC8, http://sc8.vesinet.inserm.fr:1080/accueil_fr.html.
13. Van Rhee F, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from Chronic Leukemia Working Party of European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
14. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
15. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patient with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-1092.
16. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223-229.
17. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Instit 1997; 89: 1616-1620.
18. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL-positive cells. Nat Med 1996; 2: 561-566.
19. Le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human Bcr/Abl-positive leukaemia cells with an Ab1 kinase inhibitor. J Natl Cancer Inst 1999; 91: 163-168.
20. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-1037.
21. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
22. Marin D, Marktel S, Szydlo R, et al. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alpha. Lancet 2003; 362: 617-619.
23. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic, responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002; 346: 645-652 [erratum, N Engl J Med 2001; 345: 232].
24. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
25. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 2004; 10: 68-75.
26. Kantarjian H, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in ptients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase, comparison with historic data. Cancer 2003; 98: 2636-2642.
27. Peggs K. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348: 11.
28. Goldman J. Impact of imatinib mesylate on the treatment of chronic myeloid leukaemia. American Society of Clinical Oncology (ASCO) 39th Annual Meeting 2003, Chicago, May 31-June 3.
29. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at referral center over a 16-year period. Br J Haematol 1997; 96: 111-116.
30. Othieno-Abinya NA, Nyabola LO, Kiarie GW, et al. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. East Afr Med J 2002; 79: 593-597.
31. Gratwohl A, Hermans J, Barrett AJ, et al. Allogeneic bone marrow transplantation for leukemia in European regional differences: Report from the Leukemia Working Party. Bone Marrow Transplant 1990; 5: 159-165.
32. Gratwohl A, Passweg J, Baldomero H, et al. Economics, health care systems, and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol 2002; 117: 451-468.
33. Micheli A, Coebergh JW, Mugno E, et al. European health systems and cancer care. Ann Oncol 2003; 14: 41-60.
34. Cortes JE, Talpaz M, Kantarjian HM. Chronic myelogenous leukaemia: a review. Am J Med 1996; 100: 555-570.
35. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelagenous leukaemia. Cancer 1986; 61: 1441-1446.
36. The Italian Cooperative Study Group on Chronic Myeloid leukaemia: interferon alfa-2a as compared with conventional chemotherapy for treatment of chronic myeloid leukaemia. N Engl J Med 1994; 330: 820-825.
37. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant registry. Bone Marrow Transplant 1996; 17: S5-S6.
38. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelagenous leukemia. Semin Haematol 1988; 25: 49-61.
39. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimation in 'good risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
40. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon. J Natl Cancer Inst 1998; 90: 858.
41. Micheli A, Coebergh JW, Mugno E, et al. European health systems and cancer care. Ann Oncol 2003; 14: V41-V60.